Pharmaceutical Services Negotiating Committee

Shields Health Solutions Earns URAC Accreditation in Specialty Pharmacy Services

Retrieved on: 
Wednesday, August 17, 2022
Software, Pharmaceutical, Health, Medical Devices, Data Management, Hospitals, Health Technology, Technology, Patient safety, Technology, YouTube, Patient, Risk management, Pharmaceutical Services Negotiating Committee, Education, URAC, Partnership, Blog, Â, Social media, MCI Inc., Conditional sentence, Solution, LinkedIn, Pharmacy, Shield, Medicine, Organization, Hospital, Health insurance, Facebook, Accreditation

Shields Health Solutions, the premier specialty pharmacy accelerator in the country, is proud to announce that it has earned URAC accreditation in specialty pharmacy services.

Key Points: 
  • Shields Health Solutions, the premier specialty pharmacy accelerator in the country, is proud to announce that it has earned URAC accreditation in specialty pharmacy services.
  • By achieving this status, Shields Health Solutions demonstrates commitment to quality care, enhanced processes, patient safety and improved outcomes.
  • Shields Health Solutions has a deep commitment to excellence in specialty pharmacy and the URAC accreditation marks another milestone in recognizing our high quality of care, said Kate Campagnola, Director of Accreditation.
  • By achieving URAC accreditation, Shields Health Solutions demonstrates excellence in quality care delivery and their long-term commitment to ensuring patient safety and improving outcomes.

FDA Approves First NGS-Based Companion Diagnostic to Aid in Selecting Non-Small Cell Lung Cancer Patients with HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment with ENHERTU

Retrieved on: 
Friday, August 12, 2022
Oncology, Health, FDA, Medical Devices, Research, Science, Biotechnology, FDA, Woman, ADC, United, Laboratory, Mindful Scientific Inc., ERBB2, Gene, Clinical Cancer Research, Daiichi Sankyo, HER2, Patheon, Cholangiocarcinoma, Fisher Scientific, Research, Lung cancer, NSCLC, Invitrogen, Neoplasm, Patient, Man, Thermo Fisher Scientific, Large-cell lung carcinoma, Adult, Prognosis, Pharmaceutical Services Negotiating Committee, NGS, PPD, SNV calling from NGS data, Priority review, Applied Biosystems, American Cancer Society, Science, AstraZeneca, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cdx, Food, Health, Pharmaceutical industry, Uranium, Limited

ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
  • The FDA approved ENHERTU on August 11 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 (ERBB2) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
  • The approval follows a Priority Review, granted by the U.S. FDA in April 2022.
  • Targeting HER2 Aberrations in NonSmall Cell Lung Cancer with Osimertinib.

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

Retrieved on: 
Monday, August 8, 2022
Health, Infectious Diseases, Other Science, General Health, Research, Science, Biotechnology, Public health, Laboratory, Mindful Scientific Inc., Genetic testing, Population, Drug resistance, Patheon, Research, Fisher Scientific, Invitrogen, Plasma, Thermo Fisher Scientific, Pharmaceutical Services Negotiating Committee, Therapy, MagMax, PPD, 2017 Africa Cup of Nations qualification Group M, RNA, Integrase, EDTA, Applied Biosystems, Science, HIV, UNAIDS, Health, Vaccine

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.
  • The Applied Biosystems HIV-1 Genotyping Kit will analyze expanded targets associated with HIV drug resistance that include mutations in the integrase region of the pol gene on Applied Biosystems Sanger sequencing CE instrumentation.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Residual Disease Detection in Myeloid Malignancies

Retrieved on: 
Thursday, August 4, 2022
Science, Other Science, Biotechnology, Research, Oncology, Health, Genetics, Other Health, Myeloid tissue, Multimedia, HIV disease progression rates, Laboratory, Mindful Scientific Inc., Gene, MRD, Acute myeloid leukemia, Cancer, Streamlines, streaklines, and pathlines, Patheon, Research, Fisher Scientific, Foundation, Blood, AML, Invitrogen, Patient, DNA, Thermo Fisher Scientific, Prognosis, Pharmaceutical Services Negotiating Committee, NGS, RNA, PPD, Drug development, RUO, Applied Biosystems, National, Â, Science, MD, Health, Disease, Vaccine, Medical imaging, Medical device

Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD).

Key Points: 
  • Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD).
  • View the full release here: https://www.businesswire.com/news/home/20220804005041/en/
    Ion Torrent Oncomine Myeloid MRD Assays (RUO) are the first NGS-based tests to offer simultaneous DNA and RNA analysis for myeloid MRD assessment.
  • (Photo: Business Wire)
    Acute myeloid leukemia (AML) is characterized by rapid disease progression and can be fatal if not treated promptly.
  • Detecting remaining mutations after treatment can help identify the presence of residual disease and guide patient prognosis and further treatment decisions.

Oncocyte to Participate at Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 3, 2022
Pharmaceutical Services Negotiating Committee, GLOBE, Diagnosis, Tumor microenvironment, Patient, Neoplasm, Company, Physician, OCX, Cancer, Nasdaq, Pharmaceutical industry

The live audio webcast and replay of the presentation may be accessed for 180 days on the Investors section of the companys website at https://oncocyte.com/ .

Key Points: 
  • The live audio webcast and replay of the presentation may be accessed for 180 days on the Investors section of the companys website at https://oncocyte.com/ .
  • Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage.
  • DetermaRx, DetermaIO, DetermaTx, DetermaCNI, DetermaMx and VitaGraft are trademarks of Oncocyte Corporation.

Oncocyte to Announce Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, July 27, 2022
Nasdaq, OCX, Cancer, Diagnosis, Interest, Telephone, Pharmaceutical Services Negotiating Committee, Neoplasm, GLOBE, Physician, Company, Patient, Tumor microenvironment, Pharmaceutical industry

IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022.

Key Points: 
  • IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022.
  • In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
  • DetermaRx, DetermaIO, DetermaTx, DetermaCNI, DetermaMx and VitaGraft are trademarks of Oncocyte Corporation.

NutriSense Raises $25 Million to Drive Continued Growth

Retrieved on: 
Wednesday, July 13, 2022
Health Technology, Health, Fitness & Nutrition, Pharmaceutical Services Negotiating Committee, Technology, Appetite, Physician, Capital, Growth, Health, Patient, CEO, Therapy, Pharmaceutical industry, Medical device

NutriSense , the metabolic health technology platform that couples real-time data with credentialed nutrition professionals for personalized support, announced the initial closing of a $25 million Series A round.

Key Points: 
  • NutriSense , the metabolic health technology platform that couples real-time data with credentialed nutrition professionals for personalized support, announced the initial closing of a $25 million Series A round.
  • This financing, led by 1315 Capital , a healthcare growth equity firm, will be used to drive continued growth as the company serves more consumers seeking to optimize their nutritional wellness and metabolic health.
  • NutriSense is democratizing access to personalized health monitoring, which has long been elusive for individuals looking to take their health into their own hands, said Alex Skryl, co-founder and CEO of NutriSense.
  • To date, NutriSense has grown to over 120 teammates globally and has added thousands of subscription members to its user base.

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022

Retrieved on: 
Tuesday, July 5, 2022
Health, Other Health, Other Science, Research, Science, Biotechnology, EDT, Mindful Scientific Inc., Laboratory, Science, TMO, Applied Biosystems, Pharmaceutical Services Negotiating Committee, PPD, Patheon, Thermo Fisher Scientific, NYSE, Research, Fisher Scientific, Invitrogen, Health

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2022 before the market opens on Thursday, July 28, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2022 before the market opens on Thursday, July 28, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT.
  • The earnings press release and related information can be found in that section of our website under Earnings Results.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

FDA Clears Thermo Scientific EliA RNA Pol III and EliA Rib-P Tests for Use in U.S.

Retrieved on: 
Thursday, June 9, 2022
FDA, Medical Devices, Other Health, Health, Genetics, Science, Applied Biosystems, Meta-analysis, Lupus, Arthritis, Research, Patheon, Autoantibody, Mayo Clinic College of Medicine and Science, SLE, Systemic scleroderma, Invitrogen, American College, Autoimmunity Reviews, Immunoglobulin G, PPD, Connective tissue, Scleroderma, FDA, Patient, Medical laboratory, RNA polymerase III, Fisher Scientific, BMC Medicine, Laboratory, Health, Review, Antibody, Diagnosis, Thermo Fisher Scientific, Autoimmunity, CTD, Efficiency, Systemic, Pharmaceutical Services Negotiating Committee, Elia, RNA polymerase, Mindful Scientific Inc., Medical device, Vaccine, Dermatology

Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
  • [2] The EliA RNA Pol III test completes a criteria based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
    A subset of SLE patients present with monospecific Ribosomal P antibodies.
  • The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases.
  • For more information on the Thermo Scientific EliA RNA Pol III and EliA Rib-P tests, please visit https://www.thermofisher.com/phadia .

FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE ORAL ONCOLYTIC SPECIALTY PHARMACY EARNS URAC ACCREDITATION

Retrieved on: 
Tuesday, June 7, 2022
Risk management, Â, Immunotherapy, Pharmacy, Society, LLC, American Society of Clinical Oncology, U.S. News & World Report, University of Florida Cancer and Genetics Research Complex, News, Pharmacist, Partnership, Conditional sentence, Education, ASCO, Organization, Physician, Health, GLOBE, Patient, Accreditation, URAC, FCS, Disease management, Pharmaceutical Services Negotiating Committee, Specialty pharmacy, Patient safety, Safety, Hospital, Pharmaceutical industry, Medicine, MD, Bachelor of Pharmacy

Fort Myers, Florida, June 07, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS)is proud to announce that its oral oncolytic specialty pharmacy, Rx To Go , has earned URAC accreditation for Specialty Pharmacy.

Key Points: 
  • Fort Myers, Florida, June 07, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS)is proud to announce that its oral oncolytic specialty pharmacy, Rx To Go , has earned URAC accreditation for Specialty Pharmacy.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.
  • URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.